Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bozatinix
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Bozatinix is an oral, small molecule multi-kinase inhibitor containing the active pharmaceutical ingredient cabozantinib. Developed and marketed by Laboratorio Varifarma in Argentina, it functions as a tyrosine kinase inhibitor targeting several pathways including MET, VEGFR2, AXL, and RET. By inhibiting these kinases, the drug suppresses tumor cell proliferation, migration, and angiogenesis. Bozatinix is primarily indicated for the treatment of advanced renal cell carcinoma (RCC) and as a monotherapy for hepatocellular carcinoma (HCC) in adult patients who have previously received treatment with sorafenib.
- Brand names
- Bozatinix
- Other names
- cabozantinib
02
Targets
AXL (AXL receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)ER-XMET (Mesenchymal-epithelial transition factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)TEK (Tie2)NTRK2 (Tropomyosin-related kinase receptor type B)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on Bozatinix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bozatinix.